Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.

NCT04004975 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT04004975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04004975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 25, 2019
Completion date
July 25, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma